GSK3B and neoplasm: The RKIP/GSK3β axis was first reported by Al Mulla and colleagues to have a critical impact in sustaining GSK3β activity, as a suppressor of multiple oncogenic pathways, including those of Wnt and cyclin D, known to be essential for tumor proliferation, progression, and metastasis [92].